Application of low-dose ursolic acid as medicament for treating diabetic early nephropathy

Abstract

The invention discloses an application of a low-dose ursolic acid as a medicament for treating diabetic early nephropathy. The administration mode of the ursolic acid is oral administration, and the administration dose is 50-70mg / kg weight. The invention verifies that the oral administration of the low-dose ursolic acid has a remarkable inhibition action for the activation of ERK1 / 2 and JNK accesses in an MAPK access in a renal cortex induced by diabetes and the phosphorylation level of STAT3 tyrosine and can markedly lower the expression of iNOS in the renal cortex induced by the diabetes, and more importantly, the oral administration of the ursolic acid can inhabit the glomerular hypertrophy caused by the diabetes and the accumulation of type IV collagen at glomerulus, thereby indicating that the oral administration of the ursolic acid has a remarkable therapeutic effect on the diabetic early nephropathy.

Description

technical field

[0001] The invention relates to the use of low-dose ursolic acid as a medicine for treating diabetic complications, in particular to the use of a medicine for treating early diabetic nephropathy. Background technique

[0002] Diabetic nephropathy is one of the microvascular complications of diabetes, and is the main cause of chronic kidney disease and end-stage renal failure in diabetic patients. There are many reasons for diabetic nephropathy, including hemodynamic changes in renal tissue caused by diabetes (including the imbalance of blood flow regulation of renal vessels by renin-angiotensin and kinin-prostaglandin-thromboxane), diabetes-induced renal Biochemical metabolic disorders of tissues (including increased polyol pathway, increased protein non-enzymatic glycosylation, lipid metabolism disorders, etc.) and some diabetic patients also have symptoms of hypertension, etc. About 20-30% of diabetic patients suffer from nephropathy, which manifests as ex...

Images